SELF-BREATHE RCT for Chronic Breathlessness
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04574050 |
Recruitment Status :
Recruiting
First Posted : October 5, 2020
Last Update Posted : September 9, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
A feasibility RCT comprising two groups:
- Intervention (SELF-BREATHE in addition to standard NHS care)
- Control group (standard / currently available NHS care)
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cancer COPD Asthma Bronchiectasis Adult Interstitial Lung Disease Cystic Fibrosis Chronic Heart Failure Sickle Cell Disease Renal Failure Liver Failure Post COVID-19 Dyspnea | Other: SELF-BREATHE | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 40 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | A feasibility RCT comprising two groups:
|
Masking: | Single (Outcomes Assessor) |
Masking Description: | Single blind |
Primary Purpose: | Treatment |
Official Title: | A Self - Guided, Internet - Based Intervention for Patients With Chronic Breathlessness (SELF-BREATHE): Feasibility Randomised Controlled Trial |
Actual Study Start Date : | January 11, 2020 |
Estimated Primary Completion Date : | April 4, 2022 |
Estimated Study Completion Date : | June 30, 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: SELF-BREATHE
Access to a self -guided, internet -based intervention for patients with chronic breathlessness known as SELF-BREATHE
|
Other: SELF-BREATHE
A self -guided, internet -based intervention for patients with chronic breathlessness |
No Intervention: Control
standard / currently available NHS care
|
- Feasibility: the number of patients recruited into this study over a 12-month period [ Time Frame: 12 months ]The number of patients recruited into this study over a 12-month period

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Adults ≥ 18 years of age, with the ability to read and type in English
- Access to a computer, or tablet or smart phone, with internet access and the ability to email
- Chronic breathlessness (CB) defined as; breathlessness that persists (>3months) despite optimal pharmacological treatment of the underlying disease including cancer, chronic obstructive pulmonary disease (COPD),asthma, interstitial lung disease (ILD), bronchiectasis, cystic fibrosis (CF) chronic heart failure (CHF), sickle cell disease, chronic renal/ liver failure or post COVID-19
- Chronic breathlessness at rest or on exertion; MRC dysponea score >2
- Willing to engage with short-term self-guided internet-based breathlessness intervention (SELF-BREATHE)
- Able to provide informed consent
Exclusion Criteria:
- Breathlessness of unknown cause
- A primary diagnosis of chronic hyperventilation syndrome
- Currently participating in a rehabilitation programme, e.g. pulmonary/cardiac rehabilitation

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04574050
United Kingdom | |
King's College Hospital NHS Foundation TRUST | Recruiting |
London, United Kingdom, SE5 9RS | |
Contact: Charles Reilly, PhD 02032998062 charles.reilly@nhs.net |
Responsible Party: | King's College Hospital NHS Trust |
ClinicalTrials.gov Identifier: | NCT04574050 |
Other Study ID Numbers: |
IRAS 285303 20/LO/1108 ( Other Identifier: REC / HRA ) |
First Posted: | October 5, 2020 Key Record Dates |
Last Update Posted: | September 9, 2021 |
Last Verified: | September 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Cystic Fibrosis Liver Failure Lung Diseases Dyspnea Lung Diseases, Interstitial Bronchiectasis Anemia, Sickle Cell Pancreatic Diseases Digestive System Diseases Respiratory Tract Diseases Genetic Diseases, Inborn |
Infant, Newborn, Diseases Anemia, Hemolytic, Congenital Anemia, Hemolytic Anemia Hematologic Diseases Hemoglobinopathies Respiration Disorders Signs and Symptoms, Respiratory Bronchial Diseases Hepatic Insufficiency Liver Diseases |